Study of the safety, immunogenicity and seroconversion of a hepatitis-B vaccine in malnourished children of India

Vaccine

Volumn 18, Issue 19, 2000, Pages 2009-2014

  Lakshmi, G ^a   Reddy, P Sudershan ^a   Kumar, K Ratna ^a   Bhavani, N V ^a   Dayanand, M ^a  

^a Niloufer Hospital India   (India)

Author keywords

Hepatitis B; Hepatitis B vaccine; Immunogenicity; Revac B; Seroconversion

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; REVAC B; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOGENICITY; INDIA; MAJOR CLINICAL STUDY; MALNUTRITION; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SEROCONVERSION;

CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INDIA; MALE; NUTRITION DISORDERS; RURAL POPULATION; SAFETY; VACCINES, SYNTHETIC;

EID: 0033994612     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00529-0     Document Type: Article

References (25)

1. Maynard J.E., Kane M.A., Alter J.M., Halder C.H. Control of hepatitis B by immunization: global perspectives. Viral hepatitis and liver disease. 1986;967-969 Liss, New York.
2. Report of a WHO meeting: prevention of liver cancer, Technical report no. 691. World Health Organisation, Geneva 1983, pp.8-9.
3. Hu M.D., Schenzle D., Dienhardt F., Scheid R. Epidemology of hepatitis A & B in the Shanghai area: prevalence of serum markers. Am. J. Epidemiol. 120:1984;404.
4. Sung J.L. Hepatitis-B virus eradication strategy for Asia. Vaccine. 8:(Suppl):1990;96.
5. Barin F., Perrin J., Chotard J. Cross-sectional & longitudinal epidemology of hepatitis B in Senegal. Prog. Med. Virol. 27:1981;148.
6. Toukan A. Strategy for the control of hepatitis B virus infection in the Middle East and North Africa. The Middle East Regional Study Group. Vaccine. 8:(Suppl):1990;. S117-121; discussion S134-138.
7. Bensabath G., Hadler S.C., Periera Soares M.C. Epidemological & serologic studies of acute viral hepatitis in Brazil’s Amazon basin. PAHO Bull. 21:1987;16.
8. Wong D.C., Purcell R.H., Rosen L. Prevalence of antibody to Hepatitis A and B viruses in selected populations of the South Pacific. Am. J. Epidemiol. 110:1979;227.
9. Schreeder M.T., Bender T.R., McMahon B.J., Moser M.R., Murphy B.L., Sheller M.J., Heyward W.L., Hall D.B., Maynard J.E. Prevalence of hepatitis B in selected Alaskan villages. Am. J. Epidemiol. 118:(4):1983;543.
10. Minuk G.Y., Nicolle L.E. Hepatitis infection in an isolated Canadian Inuit (Eskimo) population. J. Med. Virol. 10:1982;255.
11. Milne A., Allwood G.K., Moyes C.D., Pearce N.E., Lucas C.R. Prevalence of Hepatitis B infection in a multiracial New Zealand community. N.Z. Med. 10:1985;98-529.
12. Alter M.J. Epidemiology and Disease burden of hepatitis B and C. Antiviral therapy. 1:(Suppl 1):1996;9-14.
13. Margolis H.S., Hadler S.C., Alter M.J. The changing epidemiology of hepatitis-B in the United States and need for alternative vaccination strategies. J. Am. Med. Assoc. 263:1990;1218.
14. Chen H.L., Chang M.H., Ni H.Y., Lee P.I., Lee C.Y., Chen D.S. Seroepidemiology of hepatitis-B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 276:1996;906.
15. Chen DS, Chen HMH, Sung JL, Hsu TC, Hsu ST, Kuo YT, Lo KJ, Shih YT. The Hepatitis Steering Committee, and the Hepatitis Control Committee. Control of hepatitis B virus infection in a Hyperendemic area: A mass immunoprophylaxis programme in Taiwan. Viral Hepatitis and Liver Diseases. New York: Liss, 1988. pp.971-976.
16. Chairmonte M., Majori S., Ngatchu T., Moschen M.E., Baldo V., Benzulli G., Simoncello I., Rocco S., Bertin T., Naccarato R., Trivello R. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine. 14:(2):1996;135-137.
17. Assateerawatt A., Tanphaichitr V.S., Suvatte V., Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. Asian Pac. J. Allergy Immunol. 11:(1):1993;85-91.
18. Just M., Berger R., Just V. Reactogenicity and immunogenicity of a recombinant Hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgrad. Med. J. 63:(Suppl 2):1987;121-123.
19. Wiedermann G., Ambrosch F., Kremsner P., Kunz C., Hauser P., Simoen E., Andre F., Safary A. Reactogenicity and immunogenicity of different lots of a yeast-derived hepatitis B vaccine. Postgrad. Med. J. 63:(Suppl 2):1987;109-113.
20. Jilg W., Lorbeer B., Schmidt M., Wilske B., Zoulek G., Deinhardt F. Clincal evaluation of a recombinant Hepatitis B vaccine. Lancet. 24:(2 842130):1984;1174-1175.
21. Dentico P., Buongiorno R., Volpe A., Zavoianni A., Pastore G., Schiraldi O. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. Eur. J. Epidemiol. 8:(5):1992;650-655.
22. Jilg W., Schmidt M., Deinhardt F. Vaccination against Hepatitis B: Comparison of three different vaccination schedules. J. Infect. Dis. 160:1989;766.
23. Hadler S.C., Monzon M.A., Lugo D.R., Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa indians. Vaccine. 7:1989;106-110.
24. Scheiermann N., Gesemann M., Maurer C., Just M., Berger R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine. Feb:(Suppl):1990;S44-46.
25. Marsano L.S., Greenberg R.N., Kirkpatrick R.B., Zetterman R.K., Christiansen A., Smith D.J., De Medina M.D., Schiff E.R. Comparison of a rapid immunisation schedule to the standard schedule for adults. Am. J. Gastroenterol. 91:(1):1996;111-115.